WO2004082610A3 - Modulation of hyaluronan and cd44 interaction and uses thereof in treating disorders - Google Patents

Modulation of hyaluronan and cd44 interaction and uses thereof in treating disorders Download PDF

Info

Publication number
WO2004082610A3
WO2004082610A3 PCT/US2004/007605 US2004007605W WO2004082610A3 WO 2004082610 A3 WO2004082610 A3 WO 2004082610A3 US 2004007605 W US2004007605 W US 2004007605W WO 2004082610 A3 WO2004082610 A3 WO 2004082610A3
Authority
WO
WIPO (PCT)
Prior art keywords
interaction
hyaluronan
modulation
treating disorders
modulating
Prior art date
Application number
PCT/US2004/007605
Other languages
French (fr)
Other versions
WO2004082610A2 (en
Inventor
Robert Sackstein
Original Assignee
Brigham & Womens Hospital
Robert Sackstein
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Brigham & Womens Hospital, Robert Sackstein filed Critical Brigham & Womens Hospital
Publication of WO2004082610A2 publication Critical patent/WO2004082610A2/en
Publication of WO2004082610A3 publication Critical patent/WO2004082610A3/en

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/5044—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics involving specific cell types
    • G01N33/5047—Cells of the immune system
    • G01N33/505—Cells of the immune system involving T-cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/47—Hydrolases (3) acting on glycosyl compounds (3.2), e.g. cellulases, lactases
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/705—Assays involving receptors, cell surface antigens or cell surface determinants
    • G01N2333/70585—CD44
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/90—Enzymes; Proenzymes
    • G01N2333/91—Transferases (2.)
    • G01N2333/91091—Glycosyltransferases (2.4)
    • G01N2333/91097—Hexosyltransferases (general) (2.4.1)

Abstract

Methods of modulating the interaction of hyaluronan and CD44, screening assays to identify agents for modulating the interaction, and methods of treatment of disorders mediated by CD44-HA interaction are provided herein.
PCT/US2004/007605 2003-03-14 2004-03-12 Modulation of hyaluronan and cd44 interaction and uses thereof in treating disorders WO2004082610A2 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US45471903P 2003-03-14 2003-03-14
US60/454,719 2003-03-14

Publications (2)

Publication Number Publication Date
WO2004082610A2 WO2004082610A2 (en) 2004-09-30
WO2004082610A3 true WO2004082610A3 (en) 2007-01-04

Family

ID=33029909

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2004/007605 WO2004082610A2 (en) 2003-03-14 2004-03-12 Modulation of hyaluronan and cd44 interaction and uses thereof in treating disorders

Country Status (1)

Country Link
WO (1) WO2004082610A2 (en)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8460658B2 (en) 2003-10-10 2013-06-11 Alchemia Oncology Pty Limited Method of treating cancer and/or cellular proliferative conditions and agents targeting hyaluronan anabolism useful for same
CN1882602B (en) * 2003-10-10 2011-02-09 阿尔卡米亚肿瘤股份有限公司 The modulation of hyaluronan synthesis and degradation in the treatment of disease
WO2011051402A1 (en) * 2009-11-02 2011-05-05 Universite Libre De Bruxelles New biomarkers for determining allergy status
US9320723B2 (en) * 2010-05-03 2016-04-26 University Of Rochester Methods of treating thyroid eye disease
EP2827877B1 (en) * 2012-05-15 2019-05-08 The United States of America, as represented by The Secretary, Department of Health and Human Services Uses of antagonists of hyaluronan signaling
WO2015023691A2 (en) * 2013-08-12 2015-02-19 Benaroya Research Institute At Virginia Mason 4-methylumbelliferone treatment for immune modulation
EP4153616A2 (en) * 2020-05-18 2023-03-29 Robert Sackstein Compositions and methods for treatment of inflammatory disorders

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6001356A (en) * 1995-09-29 1999-12-14 Rush-Presbyterian-St. Luke's Medical Center Method of inhibiting tissue destruction in autoimmune disease using anti-CD44 antibodies
US6423514B1 (en) * 1996-04-22 2002-07-23 Millennium Pharmaceuticals, Inc. Mammalian hyaluronan synthases, nucleic acids and uses thereof
US6492332B1 (en) * 1995-12-12 2002-12-10 Omeros Corporation Irrigation solution and methods for inhibition of tumor cell adhesion, pain and inflammation

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6001356A (en) * 1995-09-29 1999-12-14 Rush-Presbyterian-St. Luke's Medical Center Method of inhibiting tissue destruction in autoimmune disease using anti-CD44 antibodies
US6492332B1 (en) * 1995-12-12 2002-12-10 Omeros Corporation Irrigation solution and methods for inhibition of tumor cell adhesion, pain and inflammation
US6423514B1 (en) * 1996-04-22 2002-07-23 Millennium Pharmaceuticals, Inc. Mammalian hyaluronan synthases, nucleic acids and uses thereof

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
CASEY R.C. ET AL.: "CD 44 and Beta 1 Integrins Mediate Ovarian Carcinoma Cell Migration Toward Extracellular Matrix Proteins", CLINICAL AND EXPERIMENTAL METASTASIS, vol. 18, 2000, pages 67 - 75, XP003005395 *
CHOU M.-Y. ET AL.: "Purification and Characterization of Sialidase L, a NeuACalpha2 3Gal-specific sialidase", JOURNAL OF BIOLOGICAL CHEMISTRY, vol. 269, 22 July 1994 (1994-07-22), pages 18821 - 18826, XP003005396 *
PUMMILL P.E. ET AL.: "Evaluation of Critical Structural Elements of UDP-Sugar substrates and Certain Cysteine Residues of a Vertebrate Hyaluronan Synthase", THE JOURNAL OF BIOLOGICAL CHEMISTRY, vol. 277, no. 24, 2002, pages 21610 - 21616, XP008075113 *

Also Published As

Publication number Publication date
WO2004082610A2 (en) 2004-09-30

Similar Documents

Publication Publication Date Title
WO2004063355A3 (en) Novel methods of diagnosis of metastatic cancer, compositions and methods of screening for modulators of matastatic cancer
AU2003272285A1 (en) Thienopyrrolyl and furanopyrrolyl compounds and their use as histamine h4 receptor ligands
WO2006122156A3 (en) Compounds for modulating trpv3 function
WO2007056124A3 (en) Compounds for modulating trpv3 function
WO2005055808A3 (en) Compositions and methods to diagnose and treat lung cancer
WO2005113590A3 (en) Bmp10 propeptides and related methods
WO2004075865A3 (en) Selective modulation of tlr-mediated biological activity
WO2007053189A3 (en) Compositions and methods for altering immune function
WO2004050707A3 (en) Tumor-specific recognition molecules
SG156668A1 (en) Angiopoietin-2 specific binding agents
WO2005052147A3 (en) Method of screening for a modulator of cdk4
WO2006050333A3 (en) Methods and compositions for modulating apoptosis
HK1083202A1 (en) Anti-infarction molecules
WO2004007531A3 (en) Activated checkpoint therapy and methods of use thereof
WO2004082610A3 (en) Modulation of hyaluronan and cd44 interaction and uses thereof in treating disorders
WO2007041694A3 (en) Compositions and methods for treating inflammation
WO2007025064A3 (en) METHODS OF USING SELECTIVE llβ-HSD INHIBITORS TO TREAT GLUOCORTICOID ASSOCIATED STATES
WO2005124358A3 (en) Diagnosis and treatment of siglec-6 associated diseases
WO2006078336A3 (en) Compositions and methods for the treatment and prevention of hyperproliferative diseases
WO2009017719A8 (en) Modulators of ccr9 receptor and methods of use thereof
WO2006091544A3 (en) Methods and compositions for modulating calcium channels
AU2003215190A8 (en) Methods and compositions for treating aids and hiv-related disorders using 1414, 1481, 1553, 34021, 1720, 1683, 1552, 1682, 1675, 12825, 9952, 5816, 10002, 1611, 1371, 14324, 126, 270, 312, 167, 326, 18926, 6747, 1793, 1784, or 2045 molecules.
WO2006116076A3 (en) Tab molecules
WO2004094641A3 (en) A novel method of modulating bone-realted activity
WO2005021026A3 (en) Methods for treating or ameliorating ghrelin-associated diseases and disorders

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BW BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE EG ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NA NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SY TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): BW GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LU MC NL PL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
122 Ep: pct application non-entry in european phase